Skip to main content
. 2022 Jan 26;20:22. doi: 10.1186/s12916-021-02221-z

Table 5.

Change in HbA1c values (with HbA1c denoted in mmol/mol) after gliclazide titration

Gliclazide dose after titration
0 30 40 60 80 90 120 160 240 320
-10(-13, -8)#m=57 -12(-14, -10)#m=89 -12(-14, -11)#m=174
8(4, 10)#m=44 -2(-4, 0)#m=73
13(10, 15)#m=108 -6(-7, -3)#m=109
4(2, 6)#m=49 -3(-7, 1)#m=38 -1(-6, 3)#m=33
11(9, 13)#m=91 3(2, 4)#m=171 -3(-4, -2)#m=233
-3(-6, -1)#m=34
3(2, 4)#m=172 -1(-4, 1)#m=59 -3(-6, -1)#m=113 -4(-7, -2)#m=112
1(-2, 3)#m=50 -2(-4, 1)#m=77
2(1, 4)#m=119 3(-2, 8)#m=31

Change in HbA1c values after gliclazide initiation, titration, or discontinuation. The values above the diagonal represent the instances where the medication has been initiated or up-titrated, while the values below the diagonal represent instances where the medication has been down-titrated or discontinued. The values refer to the mean difference in HbA1c (MD) and 95% confidence intervals. MD below 0 indicate a lowering in HbA1c while those above 0 indicate an increase in HbA1c. #m refers to the number of HbA1c pairs for that dose titration